Photo - Improving treatment outcomes and quality of life of patients
play_arrow
View
38028

Improving treatment outcomes and quality of life of patients

UAE
Market: Internet and IT, Consulting, Pharmacology, Robotics, Artificial Intelligence
Stage of the project: Prototype or product is ready

Date of last change: 25.04.2019
Min investment
$  50.000
Show contacts
Total required
$ 100.000
Rating
equalizer 160 из 1000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:

Idea

Overhaul cancer outcomes by offering precise and personalized treatment and improving quality of life

Current Status

We have completed MVP and ready to pilot or PoC. We have signed three pilots with major hospital groups in India, UAE.
The product is also being co-innovated by SAP.

Market

Global
17 Million Cancer Patient
US $200 Billion

ASIA
8 Million Cancer Patient
US $100 Billion

EMEA
100K Cancer Patient
US $2 Billion

Problem or Opportunity

• The survival or complete cure of cancer patients at later stages is as low as 80%.
• The treatment is inefficient and lack efficacy at later stages.
• Treatment is quite lengthy often over 2 years and often shortage of specialists create lengthy waitlists.
• Over 50% suffer psychologically while on treatment and after and quality of life degrades drastically.

Solution (product or service)

Cancer diagnosis, treatment and maintenance outcomes on patient survival and the quality of life is unacceptably inefficient and low despite being expensive, lengthy and painful journey for a patient.


The long term approach is to construct a precision medicine data platform consisting of real-world evidence data initially and subsequently building novel solutions to provide preventative care, accurate diagnostics and personalized care to overhaul cancer outcomes to improve life expectancy, reduce recurrence rates and improve quality of life of cancer patients. Please

In short term and to begin our strategy is to build a survivorship solution to collect evidences from out patients right from the diagnosis stage till the end of life to help patients survive cancer, improve quality of life and collect behavior of therapy and treatment from patients. This evidence collected would be used to personalize the solution and support being offered to patients to improve outcomes.

Competitors

Company operating in precision medicine and major global players such as SAP, Orion Health, IBM Watson or Google health are the competitors.

Advantages or differentiators

Besides being cost effective and having customer oriented business model, we provide cloud agnostics platform and tools for tertiary genotypic and phenotypic analysis, a survivorship solution and AL/ML tools for providing precision recommendations at different stages such as diagnosis, treatment and maintenance. However, the biggest differentiation is our solution is localized and customized solution.

Finance

Licences
Different licensing strategy would be used for different components which would be offered as part of the product catalog.
1- On premise the platform license is based on yearly renewal license cost.
2- Yearly renewal cloud hosted per specialty per hospital and number of patients.
3- AI models yearly production subscription cost.

Consulting
1-Based on estimated effort of resources.
2-Specialized training based on number of hours.
3-Partnership cost and certification cost.

We have raised 15K Euro in pre-seed funding round and looking for Angel/Seed funding to support business.

Business model

We would develop various models to integrate with homecare devices, mobile devices, diagnostic devices and EMR applications to provide preventative care, accurate diagnostics and personalized care. We would licence our models on yearly renewal charges but the pricing will differ for each model.
We would also earn through consulting wherein we would provide training, consulting, certification and partnerships to different companies to earn revenue as well as establish new relationships.

We would expand to global market and our business development strategy would depend on the market dynamics.

Money will be spent on

40% on Business Development, 30% on Innovation and development and 30% on customer support and relationship management.

Offer for investor

It will be decided in investor negotiation however we are open to dilute 10% share for the investment sought.

Team or Management

Risks

Competitor risks, market risk, financial risk and regulatory risk are the important one we need to protect our business assets against.

Incubation/Acceleration programs accomplishment

Accelerator program- Startupbootcamp ,
Incubation - STEP JSSTATE, Noida , India

Won the competition and other awards

Top 50 Start up by Dubai Chambers, Dubai.
Selected for Innov8 awards, Arab Health.
We cleared first few rounds in Cedars Sinai accelerator program, Florida, US.
https://www.google.com/url?q=http%3A%2F%2Fwww.startalliance.net%2Fnew%2Fdigita-health-overview,https://www.startupbootcamp.org/blog/2018/11/smart-city-dubai-startup-week-b3-digital-solutions/,
https://theaicongress.com/2018exhibitors,
https://www.arabhealthonline.com/en/whats-new/Innov8talks/Innov8talks-session.html,
https://theaicongress.com/2018exhibitors

Invention/Patent

We have filed patents and copyrights

Photos

Photo 1 - Improving treatment outcomes and quality of life of patients

Product Video

Website address

5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility203
star0
Add to favorites
Delete from favorites
share
close
thumb_up0
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Photos
Product Video
Website address